The results of the in vivo study confirm that the newly designed 177Lu-ABY-271 specifically targets HER2-expressing SKOV-3 xenografts, as the tumor uptake was significantly (p < 0.0005) higher than the uptake in HER2-negative Ramos xenografts (Figure 6). This evidence concerns the gene ERBB2 and neoplasm.